Supernus Pharmaceuticals, Inc. (SUPN) 株式分析

企業概要

Supernus Pharmaceuticals, Inc. is a biopharmaceutical entity focused on the development and commercialization of therapeutic products for the treatment of central nervous system diseases within the United States market. The company operates within the Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a specialization in creating formulations that often address specific therapeutic areas or offer cost-effective alternatives to branded medications. With a market capitalization of $2.97B, the company maintains a significant presence in the biopharmaceutical landscape, supported by an annual revenue of $718.95M and an operational workforce of 778 employees. These valuation and revenue figures indicate that Supernus holds a substantial scale relative to smaller generic drug manufacturers, suggesting a diversified product portfolio capable of generating hundreds of millions in sales while maintaining a stable employee base to support research and commercial activities.

財務健全性

The company reported a revenue of $718.95M over the trailing twelve months, yet recorded a net income of $-38,550,000, while generating an EBITDA of $44.40M. The substantial gap between the positive EBITDA and the negative net income reveals a cost structure heavily impacted by non-operating expenses, such as interest or significant tax liabilities, which erodes the bottom line despite operational profitability. Despite the reported net loss, the firm produced a free cash flow of $55.72M, indicating strong financial flexibility to fund operations, invest in research and development, or return capital without immediate reliance on external financing. The gross margin stands at an impressive 89.6%, reflecting the high value-add nature of specialty and generic pharmaceuticals, whereas the operating margin of -28.9% and profit margin of -5.4% highlight ongoing structural costs that prevent the conversion of gross profits into net earnings. On the balance sheet, the company holds cash reserves of $308.67M against total debt of $40.98M, resulting in a debt-to-equity ratio of 3.86. Although the leverage ratio appears elevated numerically, the absolute debt level is significantly lower than the cash position, suggesting a conservative liquidity stance where the company could theoretically service its debt multiple times over using existing cash. The current ratio of 1.91 indicates robust short-term liquidity, ensuring the company can comfortably meet its current liabilities with available current assets. Return on Equity is reported at -3.7% and Return on Assets at -2.1%, metrics that reveal the company is currently in a capital-intensive expansion or restructuring phase where earnings are not yet sufficient to generate positive returns on the invested equity and assets.

バリュエーション評価

The trailing twelve-month P/E ratio is N/A due to the net loss, while the forward P/E is projected at 12.23, implying that the market expects earnings to turn positive and grow sufficiently to justify a low multiple in the coming period. The price-to-book ratio is 2.79, indicating that the market values the company at a significant premium of roughly 179% over its net book value, which often reflects intangible assets like intellectual property and pipeline potential not captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 4.13 and an EV/EBITDA of 60.91, suggesting the market is willing to pay a high multiple for revenue and cash flow generation, likely anticipating future profitability from new product launches or market share gains in the CNS sector. The stock has traded within a 52-week range between a high of $59.68 and a low of $29.16; without a specific current price provided in the source data, the valuation context relies on these historical bounds to define the potential upside or downside range relative to the trading floor. The beta of 0.73 indicates that the stock's price volatility is lower than the broader market, suggesting it moves less aggressively than the S&P 500 and may serve as a less volatile component within a diversified healthcare portfolio.

Growth & Income

Supernus Pharmaceuticals reported a revenue growth rate of 21.5% year-over-year, whereas earnings growth is N/A due to the current negative net income, implying that revenue expansion is currently outpacing earnings generation as the company navigates periods of high non-operational costs. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which signifies that the firm reinvests all available cash flow and retained earnings back into business operations and strategic initiatives rather than distributing income to shareholders. This reinvestment strategy is typical for biopharmaceutical companies in the growth phase or those with significant R&D pipelines, prioritizing long-term product development over immediate income distribution to investors. The overall growth and income profile is characterized by strong top-line expansion driven by a 21.5% revenue increase and a healthy free cash flow position, even in the absence of dividend income or positive bottom-line earnings, positioning the company for potential future profitability as its CNS therapies gain market traction.